Rocket Pharmaceuticals, Inc. reports developments in rare-disease genetic medicines, including its commercial-stage therapy KRESLADI for pediatric patients with severe leukocyte adhesion deficiency-I and its broader pipeline of investigational gene therapies. Company updates commonly address FDA actions, clinical-program progress, regulatory submissions, and financial results tied to research, development, and commercial readiness.
Recurring news themes include the AAV cardiovascular portfolio, such as RP-A501 for Danon disease, RP-A601 for PKP2-arrhythmogenic cardiomyopathy, and RP-A701 for BAG3-related dilated cardiomyopathy. Rocket also reports capital and balance-sheet actions, including monetization of its Rare Pediatric Disease Priority Review Voucher, as well as presentations at healthcare conferences.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced two presentations at the European Society for Immunodeficiencies (ESID) 2020 meeting, scheduled from October 14-17, 2020. The oral presentation will update data from its Phase 1/2 trial of RP-L201 for Leukocyte Adhesion Deficiency-I (LAD-I), while an e-poster will present preclinical results for RP-L401 targeting Infantile Malignant Osteopetrosis (IMO). Both presentations highlight Rocket’s commitment to addressing significant medical needs in rare pediatric diseases.